Difference between revisions of "Talk:20.109(S16):Flow cytometry and paper discussion (Day7)"

From Course Wiki
Jump to: navigation, search
(→‎Files to download for analysis:)
(→‎WF section)
 
(33 intermediate revisions by 12 users not shown)
Line 2: Line 2:
  
 
====Instructor samples====
 
====Instructor samples====
 +
 +
[[Media:Sp16 FlowCytometry SampleKey Instructors.xlsx| Instructor FC sample key]]
 +
 +
[[Media:Sp16 Instructor FC plots 160404.pdf| Instructor FC plots]]
 +
 +
[[Media:Sp16 Instructor FC Spreadsheet 160405.xlsx| Instructor FC spreadsheet]]
  
 
====Student samples====
 
====Student samples====
 +
 +
[[Media:Sp16 FlowCytometry SampleKey TR.xlsx| TR FC sample key]]
  
 
[[Media:TR FC plots.pdf| TR FC plots]]
 
[[Media:TR FC plots.pdf| TR FC plots]]
  
 
[[Media:TR FC spreadsheet.csv| TR FC spreadsheet]]
 
[[Media:TR FC spreadsheet.csv| TR FC spreadsheet]]
 +
 +
[[Media:Sp16 FlowCytometry SampleKey WF.xlsx| WF FC sample key]]
  
 
[[Media:WF FC plots.pdf| WF FC plots]]
 
[[Media:WF FC plots.pdf| WF FC plots]]
  
−
[[Media:WF FC spreadsheet.csv| WF FC plots]]
+
[[Media:WF FC spreadsheet.csv| WF FC spreadsheet]]
  
 
===Tables for group data:===
 
===Tables for group data:===
 +
 +
<font color = red> '''Report both the median and mean calculations for each replicate within the table according to the following format:  median value, mean value''' </font color = red>
  
 
====TR section====
 
====TR section====
−
TR Red Team: '''(insert condition information here - enzymes and drug used)'''
+
TR Red Team: '''(EcoRI, BGlII, DMNB)'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 24: Line 36:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|2.2, 1.9
−
|
+
|2.4, 3.0
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|2.4, 2.2
−
|
+
|1.9, 1.0
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|3.0, 3.0
−
|
+
|2.9, 2.8
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.11, 0.05
−
|
+
|0.13, 0.12
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.17, 0.27
−
|
+
|0.04, 0.05
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0, 0
−
|
+
|0, 0
 
|-
 
|-
 
|}
 
|}
Line 51: Line 63:
  
  
−
TR Orange Team: '''(insert condition information here - enzymes and drug used)'''
+
TR Orange Team: '''(PmeI and DMNB)'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 59: Line 71:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|2.09, 1.77
−
|
+
|2.54, 2.60
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|3.04, 1.95
−
|
+
|2.58, 3.49
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|4.11, 2.09
−
|
+
|2.70, 1.65
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.24, 0.21
−
|
+
|0.21, 0.13
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.07, 0.08
−
|
+
|0.18, 0.21
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0.01, 0.03
−
|
+
|0.04, 0.02
 
|-
 
|-
 
|}
 
|}
Line 86: Line 98:
  
  
−
TR Yellow Team: '''(insert condition information here - enzymes and drug used)'''
+
TR Yellow Team: '''(BglII PstI DMNB)'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 94: Line 106:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|2.4, 2.4
−
|
+
|2.2, 2.6
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|2.2, 2.2
−
|
+
|2.4, 2.8
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|3.2, 3.0
−
|
+
|2.6, 2.2
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.18, 0.15
−
|
+
|0.18, .18
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.19, 0.61
−
|
+
|0.025, 0.030
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0
−
|
+
|0
 
|-
 
|-
 
|}
 
|}
Line 121: Line 133:
  
  
−
TR Green Team: '''(insert condition information here - enzymes and drug used)'''
+
TR Green Team: '''(PmeI and Loperamide)'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 129: Line 141:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|3.03, 2.26
−
|
+
|2.44, 2.34
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|2.88, 2.07
−
|
+
|3.05, 2.20
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|2.07, 3.01
−
|
+
|1.75, 2.12
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.25, 0.24
−
|
+
|0.19, 0.34
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.12, 0.31
−
|
+
|0.16, 0.29
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0.05, 0.02
−
|
+
|0, 0
 
|-
 
|-
 
|}
 
|}
Line 156: Line 168:
  
  
−
TR Blue Team: '''(insert condition information here - enzymes and drug used)'''
+
TR Blue Team: '''(EcoRI + BglII - Loperamide)'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 164: Line 176:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|2.252,2.358
−
|
+
|2.422,2.271
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|2.088,2.223
−
|
+
|1.758,2.218
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|2.847,3.344
−
|
+
|2.560,3.024
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.104,0.085
−
|
+
|0.146,0.204
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.133,0.109
−
|
+
|0.087,0.114
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0.005,0.002
−
|
+
|0.079,0.037
 
|-
 
|-
 
|}
 
|}
Line 191: Line 203:
  
  
−
TR Pink Team: '''(insert condition information here - enzymes and drug used)'''
+
TR Pink Team: '''EcoRI-BglII DMNB'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 199: Line 211:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|1.93, 2.21
−
|
+
|2.97, 2.39
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|2.20, 2.38
−
|
+
|0.98, 1.92
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|2.92, 2,96
−
|
+
|2.79, 2.90
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.05, 0.11
−
|
+
|0.11, 0.13
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.27, 0.17
−
|
+
|0.05, 0.03
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0, 0
−
|
+
|0,0
 
|-
 
|-
 
|}
 
|}
Line 226: Line 238:
  
  
−
TR Purple Team: '''(insert condition information here - enzymes and drug used)'''
+
TR Purple Team: '''PmeI DMNB'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 234: Line 246:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|1.772724608, 2.085453242
−
|
+
|2.600281239, 2.537742473
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|1.948901491, 3.044622474
−
|
+
|3.487826161, 2.579098259
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|2.092658688, 4.11618439
−
|
+
|1.651441549, 2.700436438
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.207545736, 0.240272044
−
|
+
|0.133947935, 0.214451077
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.084415562, 0.074686032
−
|
+
|0.208750497, 0.175961141
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0.026551063, 0.011684889
−
|
+
|0.015829439, 0.04141871
 
|-
 
|-
 
|}
 
|}
 
</center>
 
</center>
−
 
  
 
====WF section====
 
====WF section====
  
−
WF Red Team: '''(insert condition information here - enzymes and drug used)'''
+
WF Red Team: '''BglII & PstI, Loperamide'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 271: Line 282:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|1.9, 2.2
−
|
+
|2.25, 2.28
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|2.88, 2.59
−
|
+
|2.77, 2.25
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|2.97, 3.75
−
|
+
|1.71, 2.4
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.11, 0.12
−
|
+
|0.1, 0.14
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.09, 0.09
−
|
+
|0.07, 0.06
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0.04, 0.02
−
|
+
|0.02, 0.01
 
|-
 
|-
 
|}
 
|}
Line 298: Line 309:
  
  
−
WF Orange Team: '''(insert condition information here - enzymes and drug used)'''
+
WF Orange Team: ''' ECORI + BglII - Loperamide'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 306: Line 317:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|2.25, 2.36
−
|
+
|2.42, 2.27
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|2.09, 2.22
−
|
+
|1.76, 2.22
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|2.85, 3.34
−
|
+
|2.56, 3.02
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.10, 0.09
−
|
+
|0.15, 0.20
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.13, 0.11
−
|
+
|0.09, 0.11
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0.01, 0.00
−
|
+
|0.08, 0.04
 
|-
 
|-
 
|}
 
|}
Line 333: Line 344:
  
  
−
WF Blue Team: '''(insert condition information here - enzymes and drug used)'''
+
WF Blue Team: '''(PmeI Loperamide)'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 341: Line 352:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|3.02, 2.25
−
|
+
|2.43, 2.34
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|2.88, 2.07
−
|
+
|3.05, 2.20
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|2.06, 3.1
−
|
+
|1.75,2.12
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.254, 0.241
−
|
+
|0.19, 0.33
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.12, 0.31
−
|
+
|0.16, 0.29
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0.05, 0.02
−
|
+
|0, 0
 
|-
 
|-
 
|}
 
|}
Line 368: Line 379:
  
  
−
WF Pink Team: '''(insert condition information here - enzymes and drug used)'''
+
WF Pink Team: '''(PstI & BglII, Loperamide)'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 376: Line 387:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|1.90, 2.20
−
|
+
|2.25, 2.28
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|2.88, 2.59
−
|
+
|2.77, 2.25
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|2.97, 3.75
−
|
+
|1.71, 2.40
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.11, 0.12
−
|
+
|0.10, 0.14
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.09, 0.09
−
|
+
|0.07, 0.06
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0.04, 0.02
−
|
+
|0.02, 0.01
 
|-
 
|-
 
|}
 
|}
Line 403: Line 414:
  
  
−
WF Purple Team: '''(insert condition information here - enzymes and drug used)'''
+
WF Purple Team: '''PstI-BglII, DMNB'''
 
<center>
 
<center>
 
{| border="1"
 
{| border="1"
Line 411: Line 422:
 
|-
 
|-
 
|M059K mCherry:EGFP
 
|M059K mCherry:EGFP
−
|
+
|2.42, 2.43
−
|
+
|2.21, 2.58
 
|-
 
|-
 
|M059K mCherry:EGFP + drug
 
|M059K mCherry:EGFP + drug
−
|
+
|2.21, 2.20
−
|
+
|2.38, 2.79
 
|-
 
|-
 
|M059J mCherry:EGFP
 
|M059J mCherry:EGFP
−
|
+
|3.20, 2.99
−
|
+
|2.59, 2.20
 
|-
 
|-
 
|M059K mCherry:damaged EGFP
 
|M059K mCherry:damaged EGFP
−
|
+
|0.18, 0.15
−
|
+
|0.18, 0.18
 
|-
 
|-
 
|M059K mCherry:damaged EGFP + drug
 
|M059K mCherry:damaged EGFP + drug
−
|
+
|0.19, 0.61
−
|
+
|0.03, 0.03
 
|-
 
|-
−
|M059J mCherry:EGFP
+
|M059J mCherry:damaged EGFP
−
|
+
|0, 0
−
|
+
|0, 0
 
|-
 
|-
 
|}
 
|}
 
</center>
 
</center>

Latest revision as of 04:54, 13 April 2016

Files to download for analysis:

Instructor samples

Instructor FC sample key

Instructor FC plots

Instructor FC spreadsheet

Student samples

TR FC sample key

TR FC plots

TR FC spreadsheet

WF FC sample key

WF FC plots

WF FC spreadsheet

Tables for group data:

Report both the median and mean calculations for each replicate within the table according to the following format: median value, mean value

TR section

TR Red Team: (EcoRI, BGlII, DMNB)

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 2.2, 1.9 2.4, 3.0
M059K mCherry:EGFP + drug 2.4, 2.2 1.9, 1.0
M059J mCherry:EGFP 3.0, 3.0 2.9, 2.8
M059K mCherry:damaged EGFP 0.11, 0.05 0.13, 0.12
M059K mCherry:damaged EGFP + drug 0.17, 0.27 0.04, 0.05
M059J mCherry:damaged EGFP 0, 0 0, 0


TR Orange Team: (PmeI and DMNB)

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 2.09, 1.77 2.54, 2.60
M059K mCherry:EGFP + drug 3.04, 1.95 2.58, 3.49
M059J mCherry:EGFP 4.11, 2.09 2.70, 1.65
M059K mCherry:damaged EGFP 0.24, 0.21 0.21, 0.13
M059K mCherry:damaged EGFP + drug 0.07, 0.08 0.18, 0.21
M059J mCherry:damaged EGFP 0.01, 0.03 0.04, 0.02


TR Yellow Team: (BglII PstI DMNB)

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 2.4, 2.4 2.2, 2.6
M059K mCherry:EGFP + drug 2.2, 2.2 2.4, 2.8
M059J mCherry:EGFP 3.2, 3.0 2.6, 2.2
M059K mCherry:damaged EGFP 0.18, 0.15 0.18, .18
M059K mCherry:damaged EGFP + drug 0.19, 0.61 0.025, 0.030
M059J mCherry:damaged EGFP 0 0


TR Green Team: (PmeI and Loperamide)

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 3.03, 2.26 2.44, 2.34
M059K mCherry:EGFP + drug 2.88, 2.07 3.05, 2.20
M059J mCherry:EGFP 2.07, 3.01 1.75, 2.12
M059K mCherry:damaged EGFP 0.25, 0.24 0.19, 0.34
M059K mCherry:damaged EGFP + drug 0.12, 0.31 0.16, 0.29
M059J mCherry:damaged EGFP 0.05, 0.02 0, 0


TR Blue Team: (EcoRI + BglII - Loperamide)

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 2.252,2.358 2.422,2.271
M059K mCherry:EGFP + drug 2.088,2.223 1.758,2.218
M059J mCherry:EGFP 2.847,3.344 2.560,3.024
M059K mCherry:damaged EGFP 0.104,0.085 0.146,0.204
M059K mCherry:damaged EGFP + drug 0.133,0.109 0.087,0.114
M059J mCherry:damaged EGFP 0.005,0.002 0.079,0.037


TR Pink Team: EcoRI-BglII DMNB

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 1.93, 2.21 2.97, 2.39
M059K mCherry:EGFP + drug 2.20, 2.38 0.98, 1.92
M059J mCherry:EGFP 2.92, 2,96 2.79, 2.90
M059K mCherry:damaged EGFP 0.05, 0.11 0.11, 0.13
M059K mCherry:damaged EGFP + drug 0.27, 0.17 0.05, 0.03
M059J mCherry:damaged EGFP 0, 0 0,0


TR Purple Team: PmeI DMNB

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 1.772724608, 2.085453242 2.600281239, 2.537742473
M059K mCherry:EGFP + drug 1.948901491, 3.044622474 3.487826161, 2.579098259
M059J mCherry:EGFP 2.092658688, 4.11618439 1.651441549, 2.700436438
M059K mCherry:damaged EGFP 0.207545736, 0.240272044 0.133947935, 0.214451077
M059K mCherry:damaged EGFP + drug 0.084415562, 0.074686032 0.208750497, 0.175961141
M059J mCherry:damaged EGFP 0.026551063, 0.011684889 0.015829439, 0.04141871

WF section

WF Red Team: BglII & PstI, Loperamide

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 1.9, 2.2 2.25, 2.28
M059K mCherry:EGFP + drug 2.88, 2.59 2.77, 2.25
M059J mCherry:EGFP 2.97, 3.75 1.71, 2.4
M059K mCherry:damaged EGFP 0.11, 0.12 0.1, 0.14
M059K mCherry:damaged EGFP + drug 0.09, 0.09 0.07, 0.06
M059J mCherry:damaged EGFP 0.04, 0.02 0.02, 0.01


WF Orange Team: ECORI + BglII - Loperamide

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 2.25, 2.36 2.42, 2.27
M059K mCherry:EGFP + drug 2.09, 2.22 1.76, 2.22
M059J mCherry:EGFP 2.85, 3.34 2.56, 3.02
M059K mCherry:damaged EGFP 0.10, 0.09 0.15, 0.20
M059K mCherry:damaged EGFP + drug 0.13, 0.11 0.09, 0.11
M059J mCherry:damaged EGFP 0.01, 0.00 0.08, 0.04


WF Blue Team: (PmeI Loperamide)

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 3.02, 2.25 2.43, 2.34
M059K mCherry:EGFP + drug 2.88, 2.07 3.05, 2.20
M059J mCherry:EGFP 2.06, 3.1 1.75,2.12
M059K mCherry:damaged EGFP 0.254, 0.241 0.19, 0.33
M059K mCherry:damaged EGFP + drug 0.12, 0.31 0.16, 0.29
M059J mCherry:damaged EGFP 0.05, 0.02 0, 0


WF Pink Team: (PstI & BglII, Loperamide)

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 1.90, 2.20 2.25, 2.28
M059K mCherry:EGFP + drug 2.88, 2.59 2.77, 2.25
M059J mCherry:EGFP 2.97, 3.75 1.71, 2.40
M059K mCherry:damaged EGFP 0.11, 0.12 0.10, 0.14
M059K mCherry:damaged EGFP + drug 0.09, 0.09 0.07, 0.06
M059J mCherry:damaged EGFP 0.04, 0.02 0.02, 0.01


WF Purple Team: PstI-BglII, DMNB

Sample Normalized EGFP/mCherry value (replicate #1) Normalized EGFP/mCherry value (replicate #2)
M059K mCherry:EGFP 2.42, 2.43 2.21, 2.58
M059K mCherry:EGFP + drug 2.21, 2.20 2.38, 2.79
M059J mCherry:EGFP 3.20, 2.99 2.59, 2.20
M059K mCherry:damaged EGFP 0.18, 0.15 0.18, 0.18
M059K mCherry:damaged EGFP + drug 0.19, 0.61 0.03, 0.03
M059J mCherry:damaged EGFP 0, 0 0, 0
Retrieved from "http://measurebiology.org/w/index.php?title=Talk:20.109(S16):Flow_cytometry_and_paper_discussion_(Day7)&oldid=30782"